Literature DB >> 23258624

Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach.

R A Rey1, R P Grinspon, S Gottlieb, T Pasqualini, P Knoblovits, S Aszpis, N Pacenza, J Stewart Usher, I Bergadá, S M Campo.   

Abstract

Normal testicular physiology results from the integrated function of the tubular and interstitial compartments. Serum markers of interstitial tissue function are testosterone and insulin-like factor 3 (INSL3), whereas tubular function can be assessed by sperm count, morphology and motility, and serum anti-Müllerian hormone (AMH) and inhibin B. The classical definition of male hypogonadism refers to testicular failure associated with androgen deficiency, without considering potential deficiencies in germ and Sertoli cells. Furthermore, the classical definition does not consider the fact that low basal serum testosterone cannot be equated to hypogonadism in childhood, because Leydig cells are normally quiescent. A broader clinical definition of hypogonadism that could be applied to male patients in different periods of life requires a comprehensive consideration of the physiology of the hypothalamic-pituitary-testicular axis and its disturbances along development. Here we propose an extended classification of male hypogonadism based on the pathophysiology of the hypothalamic-pituitary-testicular axis in different periods of life. The clinical and biochemical features of male hypogonadism vary according to the following: (i) the level of the hypothalamic-pituitary-testicular axis primarily affected: central, primary or combined; (ii) the testicular cell population initially impaired: whole testis dysfunction or dissociated testicular dysfunction, and: (iii) the period of life when the gonadal function begins to fail: foetal-onset or postnatal-onset. The evaluation of basal testicular function in infancy and childhood relies mainly on the assessment of Sertoli cell markers (AMH and inhibin B). Hypergonadotropism should not be considered a sine qua non condition for the diagnosis of primary hypogonadism in childhood. Finally, the lack of elevation of gonadotropins in adolescents or adults with primary gonadal failure is indicative of a combined hypogonadism involving the gonads and the hypothalamic-pituitary axis.
© 2012 American Society of Andrology and European Academy of Andrology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23258624     DOI: 10.1111/j.2047-2927.2012.00008.x

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  32 in total

1.  Leydig Cell Function in Male Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study.

Authors:  Wassim Chemaitilly; Qi Liu; Laura van Iersel; Kirsten K Ness; Zhenghong Li; Carmen L Wilson; Tara M Brinkman; James L Klosky; Nicole Barnes; Karen L Clark; Rebecca M Howell; Susan A Smith; Matthew J Krasin; Monika L Metzger; Gregory T Armstrong; Michael W Bishop; Hanneke M van Santen; Ching-Hon Pui; Deo Kumar Srivastava; Yutaka Yasui; Melissa M Hudson; Leslie L Robison; Daniel M Green; Charles A Sklar
Journal:  J Clin Oncol       Date:  2019-09-26       Impact factor: 44.544

2.  Hypogonadism: Easy to define, hard to diagnose, and controversial to treat.

Authors:  Joshua Sterling; Aaron M Bernie; Ranjith Ramasamy
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 3.  The role of the prostate in male fertility, health and disease.

Authors:  Paolo Verze; Tommaso Cai; Stefano Lorenzetti
Journal:  Nat Rev Urol       Date:  2016-06-01       Impact factor: 14.432

Review 4.  Paediatric and adult-onset male hypogonadism.

Authors:  Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi
Journal:  Nat Rev Dis Primers       Date:  2019-05-30       Impact factor: 52.329

Review 5.  Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment.

Authors:  Ulrich Boehm; Pierre-Marc Bouloux; Mehul T Dattani; Nicolas de Roux; Catherine Dodé; Leo Dunkel; Andrew A Dwyer; Paolo Giacobini; Jean-Pierre Hardelin; Anders Juul; Mohamad Maghnie; Nelly Pitteloud; Vincent Prevot; Taneli Raivio; Manuel Tena-Sempere; Richard Quinton; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2015-07-21       Impact factor: 43.330

Review 6.  The association of peripubertal serum concentrations of organochlorine chemicals and blood lead with growth and pubertal development in a longitudinal cohort of boys: a review of published results from the Russian Children's Study.

Authors:  Oleg Sergeyev; Jane S Burns; Paige L Williams; Susan A Korrick; Mary M Lee; Boris Revich; Russ Hauser
Journal:  Rev Environ Health       Date:  2017-03-01       Impact factor: 3.458

Review 7.  Testosterone therapy in children and adolescents: to whom, how, when?

Authors:  Maria Camila Suarez A; Joseph M Israeli; Eliyahu Kresch; Leon Telis; Daniel E Nassau
Journal:  Int J Impot Res       Date:  2022-01-07       Impact factor: 2.896

8.  Clomiphene Citrate Effectively Increases Testosterone in Obese, Young, Hypogonadal Men.

Authors:  Sachin V Bendre; Pamela J Murray; Shehzad Basaria
Journal:  Reprod Syst Sex Disord       Date:  2015-11-13

9.  Gonadal function in males with autoimmune Addison's disease and autoantibodies to steroidogenic enzymes.

Authors:  M Dalla Costa; G Bonanni; S Masiero; D Faggian; S Chen; J Furmaniak; B Rees Smith; R Perniola; G Radetti; S Garelli; S Chiarelli; M P Albergoni; M Plebani; C Betterle
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

10.  Hypogonadism as a Reversible Cause of Torsades de Pointes in Men.

Authors:  Joe-Elie Salem; Xavier Waintraub; Carine Courtillot; Christian M Shaffer; Estelle Gandjbakhch; Carole Maupain; Javid J Moslehi; Fabio Badilini; Julien Haroche; Paul Gougis; Veronique Fressart; Andrew M Glazer; Francoise Hidden-Lucet; Philippe Touraine; Benedicte Lebrun-Vignes; Dan M Roden; Anne Bachelot; Christian Funck-Brentano
Journal:  Circulation       Date:  2018-07-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.